Oryzon Genomics SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Carlos Manuel Buesa Arjol
- Full Time Employees
- 46
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Sant Ferran 74 Barcelona Spain 08940
- IPO Date
- Dec 14, 2015
- Website
- oryzon.com
- Similar Companies
- Business
- Oryzon Genomics S.A. (ORY.MC) is a clinical-stage biopharmaceutical company and the European leader in epigenetics-based therapeutics, focusing on personalized medicine approaches for central nervous system (CNS) disorders and oncology; the company develops proprietary drug candidates through Phase II clinical trials before deciding on in-house advancement, partnering, or out-licensing for late-stage development and commercialization. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, with additional offices in Boston, Massachusetts, and San Diego, California, United States, Oryzon operates primarily in Europe and the United States, targeting patients with cancer, neurodegenerative diseases, psychiatric disorders, and rare neurodevelopmental conditions through its advanced pipeline of lysine-specific demethylase 1 (LSD1) inhibitors and other epigenetic targets. Its core products include vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor in Phase III-ready development for agitation/aggression in borderline personality disorder (BPD; PORTICO-2 trial protocol submitted to FDA in 1H2025), negative symptoms in schizophrenia (EVOLUTION Phase IIb trial ongoing), and genetically defined subpopulations in autism spectrum disorder (ASD), Alzheimer's disease, and other neurodevelopmental syndromes; iadademstat (ORY-1001), a highly selective LSD1 inhibitor in Phase II for acute myeloid leukemia (AML; including combinations with azacitidine, gilteritinib, and venetoclax), small cell lung cancer (SCLC; combinations with platinum/etoposide and PD-1/PD-L1 inhibitors), neuroendocrine tumors, and expanding into non-oncological hematology such as sickle cell disease and essential thrombocythemia; ORY-3001, a selective LSD1 inhibitor in preclinical development for non-oncological diseases; and ORY-4001, a histone deacetylase 6 (HDAC-6) inhibitor clinical candidate nominated for Charcot-Marie-Tooth disease (CMT) and amyotrophic lateral sclerosis (ALS); the company also maintains a proprietary platform for biomarker identification and target validation in malignant and neurological diseases. Among recent developments, Oryzon secures a 13.26 million euro non-refundable grant (approximately 15 million USD) in May 2025 through the European IPCEI Med4Cure project for its VANDAM initiative, funding personalized medicine validation of vafidemstat in aggression subtypes of ASD (including Phelan-McDermid and Fragile-X syndromes) and iadademstat in rare neuroendocrine cancers and genetically driven hematological diseases through August 2026; the company raises over 60 million USD in non-dilutive and equity financing during the first half of 2025, including a 30 million euro capital increase via accelerated bookbuild in April 2025 to bolster its balance sheet, prepare a potential Nasdaq IPO, and expand neuroscience and oncology programs, while terminating a prior convertible bonds financing; Oryzon strengthens its intellectual property portfolio in September 2025 with Decisions to Grant from the Australian and European Patent Offices for iadademstat combinations with PD-1/PD-L1 inhibitors in cancer (valid to at least 2040) and vafidemstat in behavioral alterations like BPD, ASD, and schizophrenia-related social withdrawal (valid to at least 2038); it advances strategic collaborations, including a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI) for iadademstat in hematologic and solid tumors (with Phase I/II trials in SCLC and AML ongoing at sites like Memorial Sloan Kettering), and shifts toward a CNS-focused strategy by exploring partnerships for iadademstat while enhancing its value through investigator-initiated studies; additionally, Oryzon bolsters its clinical, regulatory, and strategic teams with late-stage development experts following FDA feedback on vafidemstat's PORTICO trial.
Company News
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
ORYZON to Participate in Upcoming Events in November
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
ORYZON to Host Virtual KOL Event on July 9, 2025
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
ORYZON to Provide Corporate Progress Updates at Several Events in March-April
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting